



**Address:** Instituto Oftalmobiología Aplicada (IOBA), Facultad Medicina, Universidad de Valladolid, Ramón y Cajal, 7, Valladolid 47005, Spain. Tel 34-983-184750/Fax 34-983-423235/e-mail <calonge@ioba.med.uva.es>

**Date and place of birth:** March 28, 1960. Segovia (Cuéllar), Spain.   Passport number: P ESP P634271 A0925595200

Medical Licence number (Nº de colegiado): 474703809

**LANGUAGES:** Spanish (native language); English (read, written, spoken); French (read)

## EDUCATION AND PREDOCTORAL TRAINING

- 1983: MD (Medical Doctor) degree at the University of Valladolid, Valladolid, Spain.
- 1983-87: Specialist in Ophthalmology. Residency in Ophthalmology, University Hospital, Valladolid, Spain.
- 1987: PhD degree in Visual Sciences. Doctoral Thesis on Ocular Allergy.

## POSTDOCTORAL TRAINING

- 1/1988-12/1988: Postdoctoral Research Fellowship in Ocular Immunology, Schepens Eye Research Institute of the Retina Foundation (Preceptor: Mathea R. Allansmith, MD), Boston, Harvard Medical School, Cambridge, Massachusetts, USA.
- 1/1989-12/1989: Postdoctoral Fellowship in Ocular Immunology, Immunology and Uveitis Service and Hilles Immunology Laboratory, Massachusetts Eye and Ear Infirmary (Preceptor: C. Stephen Foster, MD, FACS), Boston, Harvard Medical School, Cambridge, Massachusetts, USA.
- 1/7/1992-15/9/1992: Short-term stay. Immunology and Uveitis Service and Hilles Immunology, Laboratory, Massachusetts Eye and Ear Infirmary (Preceptor: C. Stephen Foster, MD, FACS), Boston, Harvard Medical School, Cambridge, Massachusetts, USA.
- 24/6/1996-3/8/1996: Short-term stay. Immunology and Uveitis Service and Hilles Immunology, Laboratory, Massachusetts Eye and Ear Infirmary (Preceptor: C. Stephen Foster, MD, FACS), Boston, Harvard Medical School, Cambridge, Massachusetts, USA.

## ACADEMIC APPOINTMENTS

- 1990-5/95: Assistant Professor of Ophthalmology, University of Valladolid
- 5/1995-9/1996: Associate Professor of Ophthalmology, University of Valladolid.
- 10/1996-04/2005: Professor of Ophthalmology, University of Valladolid.
- 05/2005-present: Full Professor ("Catedrático") of Ophthalmology, University of Valladolid.

## INSTITUTE (RESEARCH) APPOINTMENTS

- 1990-present: Principal Investigator; Director of the Ocular Surface Research Group, IOBA, University of Valladolid

## CLINICAL APPOINTMENTS

- 1990-1994: Director, Ocular Surface and Immunology Unit, Department of Ophthalmology, University Hospital, Valladolid, Spain.
- 1993-present: Director, Ocular Immunology Unit, IOBA, University of Valladolid, Valladolid, Spain.

## RESEARCH GRANTS (as principal investigator)

- 1991-93: Grant from the Ministry of Education (DCICYT, PM90-0013): "Ocular surface alteration by long-term application of drops and its influence in ocular allergic reactions".
- 1992-93: Grant from Sandoz Pharma S.A.E. (Spain): "Immunomodulation of corneal transplantation rejection by biopolymers of ciclosporine in the anterior chamber. Experimental study".

- 1992: Grant from Fisons Pharmaceuticals (UK): "Efficacy of 2% Nedocromil sodium and 4% sodium cromoglycate in a model of allergic conjunctivitis in the guinea pig".
- 1992: Grant from the University of Valladolid (Spain) for a two-month period stay at the Massachusetts Eye and Ear Infirmary, Boston, USA.
- 1993-95: Grant from Sandoz Pharma S.A.E. (Spain): "Inmunomodulation of corneal transplantation rejection by nanocapsules loaded with ciclosporine A. Experimental study".
- 1994-95: Grant from Fisons Pharmaceuticals (UK): "Cytokine release and expression of adhesion molecules by conjunctival epithelial cells. Modulation by 2% nedocromil sodium".
- 1994-95: Grant from the Ministry of Education (Spain) (FIS 94/1610): "Predictive value of sIL-2R and TNF-alfa in the prevention of graft rejection in high risk corneal transplantation in mice".
- 1995: Grant from the Junta de Castilla y León (Spain) (no. 28.540): "Prevention and treatment of immune rejection of penetrating keratoplasty in the rat by nanocapsules loaded with cyclosporine A".
- 1996-97: Grant from Fisons Ibérica (Spain): "Clinical study on the efficacy of Nedocromil".
- 1996-97: Grant from the Ministry of Education (Spain) (FIS 96/1446): "Treatment of intraocular inflammation (uveitis) with a controlled-release system (microspheres) loaded with steroids".
- 1996-97: Grant from Rhône-Poulenc Rorer Pharmaceuticals (UK): "Cytokine release and expression of adhesion molecules by conjunctival epithelial cells. Modulation by 2% nedocromil sodium".
- 1998-2000: Grant from the Ministry of Education of Spain (FIS 98/1412): "Cultured human conjunctival transplantation: search for a biologic support and a long-term preservation system".
- 12/99-12/00: Grant from Allergan Inc laboratories (USA). Antiinflammatory modulation for dry eye. In vitro study.
- 09/2000-08/01: Artículo 11 de la LRU con los Laboratorios Allergan Inc (USA) and Allergan Ltd (UK). Clinical Trial 192371-503-01 (fase IIIb): Safety and efficacy of Cyclosporin 0.05% unpreserved ophthalmic solution vs unpreserved artificial tears in patients with moderate to severe keratoconjunctivitis sicca.
- 09/2000-08/01: Grant from Allergan Inc laboratories (USA): "Influence of topical cyclosporin A on the expression of mucin mRNAs in conjunctival impression cytology specimens from Dry Eye patients".
- 09/2000-12/02: Grant from Allergan Inc laboratories (USA), collaborative research. "Presence of neurotransmitter receptors in cultured epithelial cells from human conjunctiva".
- 01/2002-12/2002: Grant from Allergan Inc (USA), collaborative research. "Inflammatory markers and neurotransmitter receptors in conjunctival epithelial cells".
- 03/2002-03/2002: Grant from Allergan S.A.E. (España). "Conjunctival transplantation for ocular surface pathology".
- 2002-2004: Ministry of Science and Technology of Spain: FEDER-CICYTT MAT2001-1853-C02-02 (Science and Technology Ministry of Spain). Research project: Bioactive materials based on bioelastic polymers containing cell adhesion molecules sequences for tissue engineering at the ocular surface level. Project coordinated with the Department of "Physics of the condensed materia" of the University of Valladolid, Valladolid, Spain (Dr. J.C. Rodríguez-Cabello).
- 01/2003-12/2003: Grant from Allergan Inc (USA), collaborative research. Research project: "Efficacy of different antiallergic drugs on eyelid swelling of allergic origin".
- 01/2003-12/2003: Grant from Allergan Inc (USA), collaborative research. Research project: "Neurotransmitter receptors in the inflamed conjunctival epithelium".
- 01/2003-12/2006: Grant from Bausch & Lomb Inc (USA). Project (Clinical Trial): Fluocinolone Acetonide Implant in noninfectious uveitis patients (short title).

- 04/2003-04/2005: Junta de Castilla y León (autonomic Government), Ref. UV08/03 (Grants for the development of resources for University teaching). Project: "Elaboration of guidelines to support teaching on the subject "Optometry and Contactology in the Career Optics and Optometry".
- 0/12/2002-29/12/2003 (3 more years upon evaluation). National Network on Cooperative Research in Ophthalmology. Subproject: Ocular Surface Research (Principal Investigator and coordinator of the subproject).
- 04/2003-4/2008: Research unrestricted grant from Allergan Inc (USA) and Allergan Ltd, UK. Project: Collaborative Agreement to develop the Allergan/IOBA Ocular Surface Disease Program.
- 08/2004-08/2007: Ministry of Science and Education of Spain: FEDER-CICYT MAT2004-03484-C02-02. Project: Ocular tissue bioengineering: development of "stem cells-elastic biopolymers" systems for ocular surface reconstruction. Project coordinated with the Bioforge Group (Physics Department) of the University of Valladolid, Valladolid, Spain (Dr. J.C. Rodriguez-Cabello).
- 22/11/2005-21/11/2007: Grant from Federation of Saving Banks of Castile and Leon (Research Projects on Stem Cells for Clinical Applications). Project: Tissue engineering for ocular surface reconstruction: transplant of stem cell-byopolymer complexes .
- 2005-2008: Grant from Junta de Castilla y Leon (Programa de Apoyo de la Junta de Castilla y León a Proyectos de Investigación tipo C "Grupos de excelencia"). VA003C05. Development of biopolymeric niches for the ex vivo expansion of stem cells and their further transplantation to the ocular surface.
- 03/08/2006: CB06/01/0003.CIBER "Bioengineering, Biomaterials y Nanomedicine". Instituto de Salud Carlos III, Ministry of Health, Spain
- 06/10/2006: Ministry of Industry, Tourism and Trade. Development of environment chamber for the standardization of parameters and study of its impact in the ocular pathology . Reference IDI-20060676.
- 05/12/2006-04/12/2010: National Network on Cooperative Research in health. Cell Therapy network. (TerCel).
- 06/2007-05/2008: National Network on Cooperative Research in health. Cell Therapy network. Ophthalmology (OSG). Project: Ocular surface tissue bioengineering
- 30/12/2007-31/12/2008: Instituto de Salud Carlos III, Ministry of Health, Spain. Cell Therapy network (TerCel). Project: Autologous transplantation of limbal epithelial stem cells expanded ex vivo for the reconstruction of corneal blindness.
- 12/06/2008: Junta de Castilla y Leon (Group GR217): Group of excellence category in the Autonomic region of Castilla and León.
- 07/08/2008-07/08/2010: Ministry of Science and Education of Spain: SAF2008-01114-E. Optometry network.
- 10/2008-10/2009: Grant from Junta de Castilla y Leon. Reference: SA673/VA/19/08: Evaluation of Belmonte's gas esthesiometer.

## MAJOR RESEARCH INTEREST AT PRESENT

- Dry Eye Disease: role of conjunctival epithelium in its pathophysiology. New therapeutic options.
- Ocular allergy: role of conjunctival epithelial cells as antigen presenting cells. New therapeutic options.
- Ocular surface bioengineering and stem cell therapy.

## DIRECTION OF DOCTORAL THESES

- 6/1992: Risk factors for corneal graft failure and immune rejection. Fredeswinda Romero, Valladolid, Spain. Sobresaliente.
- 4/1994: Long-term application of antiglaucoma commercial preparations in the ocular surface. Experimental study. Cesar Berrocal, Valladolid, Spain. Apto cum laude.
- 6/1995: Development of an experimental model of ocular allergy by immunization with an aeroallergen. Jesús Merayo, Valladolid, Spain. Co-direction with Stephen Foster, MD, Harvard Medical School, Boston, USA. Apto cum laude.
- 2/1997: Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Ramón Juberías, Valladolid, Spain. Apto cum laude.
- 3/1997: Human in vitro conjunctival surface: development, characterization, and validation. Yolanda Diebold, Valladolid, Spain. Apto cum laude.

- 12/1998: Prevention of experimental corneal graft rejection by a single dose of cyclosporin A formulated in microspheres. Ana Isabel Valledado. Co-direction with M. Isabel López, IOBA, University of Valladolid. Sobresaliente "cum laude".
- 13/02/2004: Microspheres loaded with dexamethasone intravitreally in experimental uveitis. Ana Díez. Co-direction with M. Isabel López, IOBA, University of Valladolid. Sobresaliente "cum laude".
- 05/09/2008: Changes in the ocular surface secondary to the exposition to an adverse environment created in an environmental chamber. M. Jesus Gonzalez. IOBA, University of Valladolid. Sobresaliente "cum laude".

## VISITING APPOINTMENTS AND SPECIAL LECTURES (Internationals only)

- 5/90: Invited speaker. I International Symposium on Ocular Inflammation, Alicante, Spain.
- 5/92: Invited pannelist. European Ocular Surface Diseases Advisory Panel, Brussels, Belgium.
- 7/92: Invited speaker. Ocular Allergy and Immunopathology Simposium, and Uveitis Course; XXV National Meeting of the Colombian Society of Ophthalmology, Bogota, Colombia.
- 11/94: "Atopic keratoconjunctivitis", "The use of immunosuppressives and immunomodulation in ocular inflammation". Eye Research Meeting, Medical Research Foundation "Sankara Nethralaya", Madras, India.
- 11/94: "Atopic keratoconjunctivitis". XI International Congress of Eye Research, New Delhi, India.
- 5/95: Invited pannelist. "AIDS: Ocular manifestations". McGill Intal Symposium on Uveitis, McGill University, Montreal, Canada.
- 5/1996: Invited speaker. "Queratoconjuntivite atopica. Symposium on Ocular Allergy. San Joao Hospital, Porto, Portugal.
- 6/1997: Immunosuppressive Therapy for Non-infectious Uveitis. Session: Uveitis (S009). XIth Congress of the European Society of Ophthalmology. Budapest, Hungary.
- 6/1997: Invited pannelist. Cyclosporine European Regional Advisory Panel, Budapest, Hungary. Organized by Allergan Ltd.
- 27-1/6-7/98: Session moderator: "External Ocular Disease"; Inflammation of the Ocular Surface". Firt Combined International Symposium on Ocular Immunology and Inflammation. Amsterdam, Holland.
- 22-25/07/98: Invited speaker: Classification of Ocular Allergic Disorders Conditions. Challenges, Strategies and Tools to Optimize the Management of Ocular Allergy. I International Symposium. Monte Carlo, France.
- 12/05/1999: Current studies on atopic keratocojunctivitis. Special Interest Group (SIG) Meeting: Future Frontiers in Patient Oriented Ocular Allergy Research. Annual Meeting of the ARVO. Fort Lauderdale, Fl, USA.
- 23-24/06/99: Invited speaker: Ocular allergy. Association with allergic dermatitis. II International Symposium on Ocular Allergy. Leeds, England.
- 08/10/99: Therapeutic Interventions for Dry Eye. Special Interest Symposium: Inflammatory Mechanisms in Dry Eye (moderators: Steve Wilson, Tony Bron). EVER Meeting, Palma de Mallorca.
- 08/10/99: Ocular Allergy, association with allergic dermatitis. Special Interest Symposium: Ocular Allergy I (moderator: Khalid Tabbara). EVER Meeting, Palma de Mallorca.
- 10-13/2/00: The role of anti-inflammatory drugs in the therapeutic regimen of dry eyes/keynote lecture. 3rd International Symposium on Ocular Pharmacology and Pharmaceutics. Lisbon, Portugal.
- 08/04/2000: Different types of ocular allergies: a common therapeutic management?. I Coloquio Internacional de Oftalmologia, FML 2000 HSM. Faculdade de Medicina de Lisboa-Sociedade Portuguesa de Oftalmología. Hotel Sheraton Lisboa, Lisboa, Portugal.
- 03/09/2000: Clinical spectrum and Therapeutic management of atopic keratoconjunctivitis. European Science Foundation Exploratory Workshop: "Immunotherapy Strategies in Chronic Allergic Eye Disease". Moorfields Eye Hospital, London.
- 4-15/03/2002: Dry Eye Syndromes. Ettal-Workshop: Immunology of the Ocular Surface and Tear Film. Ettal, Germany.
- 23/04/2002: The pathophysiology of ocular allergy. Zaditen in Allergic Eye Disease. Satellite session at the XXIX International Congress Of Ophthalmology. Sydney, NSW, Australia.

- 31/05/2002:-Advances on membrane stabilizing agents for ocular surface allergies. 1<sup>st</sup> European Congress: Advances in Diagnosis and Treatment of Ocular Surface Diseases. Santa Margherita Ligure, Italy.
- 04/10/2002: Interface between allergic and dry eye disease. Special Interest Symposium: Major Advances in Dry Eye Research. The EVER meeting, Alicante, Spain.
- 06/02/2003. Dry Eye: 1. Clinical Signs and symptoms, how to find out what is what?; 2. Treatment Options Today, which lubricant and why?. Allergan Asia Pacific Dry Eye Advisory Board. Singapore.
- 07/06/2003: International Advisory Board Meeting for Epinastine (Allergan). Hotel Sofitel, Madrid, Spain.
- 09/06/2003: New treatment approaches for Dry Eye Syndrome. Corneal Health: Issues for LASIK, Ocular Surgery and Glaucoma. 14<sup>th</sup> Congress of the European Society of Ophthalmology (SOE). Madrid, Spain.
- 06/12/2003: “Doença alérgica ocular” (Ocular allergic disease). Course 4: Doenças Oculares Extremas (Ocular Surface Diseases). XLVI Congresso da Sociedade Portuguesa de Oftalmologia. Vilamoura, Portugal.
- 07/12/2003: O que ha de novo em inflamação ocular? (What is new in ocular inflammation?). XLVI Congresso da Sociedade Portuguesa de Oftalmologia. Vilamoura, Portugal.
- 14/06/2004: Treatment of allergic conjunctivitis. Symposium: Allergic conjunctivitis: mechanisms and management. XXIII Congress of the European Academy of Allergology and Clinical Immunology (EAACI). Amsterdam, Holland.
- 06/11/2004: Alergias en la infancia. XIII Reunión Anual de la Sociedad Castellano-Leonesa de Oftalmología. Miranda de Ebro, Burgos, Spain.
- 18/11/2004:Keynote Lecture: Conjunctival epithelium biology: role of conjunctival epithelial cells in vitro. 4th International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes (TFOS): Basic Science and Clinical Relevance. Fajardo, Puerto Rico.
- 21-22/01/2005: Experimental models of corneal/conjunctival inflammation (Group 1: signalling pathways). Cullen Symposium on Cornea and Ocular Surface Inflammation. Cullen Eye Institute, Baylor College of Medicine, Texas Medical Center, Houston, TX, USA.
- 17/02/2005: Current therapies/related systemic diseases (When the ocular surface reveals what is going on elsewhere). Asia Pacific Special Interest Group Symposium: Ophthalmic Disease Battlefield: Maintaining the Health of the Ocular Surface. 2<sup>nd</sup> SERI-ARVO Meeting on Research in Vision and Ophthalmology. Singapore.
- 19/05/2005: Medical Treatment for Dry Eye. Session: New insights and treatments for Dry Eye. 8<sup>th</sup> Symposium of the International Ocular Inflammation Society (IOIS). Granada. Spain.
- 24/06/2005: “Management of Atopic Keratoconjunctivitis”. 35<sup>th</sup> ECLSO (European Contact Lens Society of Ophthalmologists) Congress/12<sup>th</sup> MCLOSA (Medical Contact lens and Ocular Surface Association) Meeting. The Royal College of Physicians of London. London. UK.
- 19/09/2005: “Dry Eye Syndrome”. Satellite Symposium: New Era in Dry Eye Treatment. 39<sup>th</sup> Turkish National Ophthalmology Congress. Antalya, Turquía.
- 15/11/2005: “Enfermedad alérgica a nivel ocular”. Sociedad Castellano-Leonesa de Alergia e Inmunología Clínica. Colegio de Médicos, Valladolid, Spain.
- 18/11/2005: “Medicina Regenerativa y Terapia Celular en la Superficie Ocular”. Reunión Científica “Investigación con Células Madre”. Colegio Oficial de Biólogos de Castilla y León (Consejería de Sanidad, Junta de Castilla y León), León, Spain.
- 03/03/2006: Conjuntivitis alérgica en la infancia. II Curso Exploración Pediátrica y Estrabismo. Universidad de Sevilla, Sevilla, Spain.
- 24/03/2006: Síndrome de Ojo Seco: “Las Nuevas Piezas del Puzzle”. Symposium: Últimos Avances en Enfermedades Inmunológicas Oculares. Servicio de Oftalmología, Hospital Clínico, Barcelona, Spain.

- 22/05/2006: Dry Eye Syndrome pathophysiology (2 hr). Master: Optometry and Visual Sciences. School of Optometry, Universidad Politécnica de Tarrasa, Barcelona, Spain.
- 03/07/2006. Choosing a lubricant. Symposium on Ocular Therapeutics. 91st Oxford Ophthalmological Congress. Oxford, UK.
- 02/11/2006. Role of Conjunctival Epithelial Cells in Inflammation (invited speaker). Session 7. Conjunctival immunity and inflammation. XVII International Congress of Eye Research (ICER). Buenos Aires, Argentina.
- 27/01/2007. Enfermedades alérgicas de la superficie ocular: fisiopatología, clínica y tratamiento. Curso: Ojo Seco y Superficie Ocular. Instituto Barraquer, Barcelona, Spain.
- 02/02/2007. Manejo de la EICH crónico ocular. XV Seminario sobre Trasplante con Células Madre Stem Periféricas (TASPE). Granada, Spain
- 31/03/2007. Síndrome de Ojo Seco: nuevas piezas en el rompecabezas. Symposium: Biopolímeros y Superficie Ocular: lentes de contacto. Universidad Politécnica de Valencia-CSIC, Xàtiva, Valencia, Spain.
- 26/04/2007. Uveítis infecciosa frente a no infecciosa: curación vs. Control. Seminario del Departamento de Oftalmología, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
- 17/05/2007. Afectación Ocular por EICHc. Seminario en Enfermedad Injerto contra Huésped crónico. Grupo Español de Trasplante Hematopoyético y Terapia Celular. Madrid, Spain.
- 09/06/2008. Management of persistent allergic inflammation in the ocular surface. XXVII Congress of the European Academy of Allergology and Clinical Immunology. Barcelona. *Spain*.
- 17/05/2008. Clinical Management of Inflammation in Dry Eye. Panel: New Definitions of Dry Eye Syndrome and Treatment Strategies. 9<sup>th</sup> Congress of the International Society of Dacriology and Dry Eye. Estambul. Turquía.
- 09/06/2008. Management of Persistent Allergic Inflammation in the Ocular Surface. Workshop: Ocular Allergy. XXVII Congress of the European Academy of Allergology and Clinical Immunology (EAACI). Barcelona, España. *Spain*.
- 2-6/08/2008. "Ojo Seco" (Día de la Subespecialidad); Uveítis infecciosas vs no infecciosas"; "Uveítis: técnicas en biología molecular y estudio biopsia" (Curso Transcongreso asignado: Métodos diagnósticos en uveítis); Uveítis: edema macular (Curso transcongreso asignado: Manejo actual del edema macular uveítico). XXVIII Congreso Mexicano de Oftalmología. Mérida, Yucatán, México.
- 24-29/09/2008. Co-organizador de la Sesión: Immunology of Dry Eye. Contribución: "Transforming growth factor beta (TGF- $\beta$ ) and the ocular surface epithelial cells. XVIII International Congress of Eye Research (ICER). Beijing, China.
- 7-8/11/2008. Uveitis Subspecialty Day. Infectious uveitis panelist. American Academy of Ophthalmology. Atlanta, GA, USA.

### INSTRUCTOR/DIRECTOR OF TEACHING COURSES

- 04/1989: Senior Instructor. I Ocular Immunology Course. Foreign guest: Mathea Allansmith, MD. University of Valladolid, Valladolid, Spain.
- 06/1991: Senior Instructor. II Ocular Immunology Course (main topic: Ocular Allergy). Foreign guest: C. Stephen Foster, MD. University of Valladolid, Valladolid, Spain.
- 06/1993: Senior Instructor. III Ocular Immunology Course (main topic: immune rejection of corneal transplantation). Foreign guest: John Chandler, MD. University of Valladolid, Valladolid, Spain.
- 06/1995: Senior Instructor. IV Ocular Immunology Course (Uveitis), Sevilla, Spain. Foreign guest: C. Stephen Foster, MD. University of Valladolid, Valladolid, Spain.
- 06/1995: Associate Instructor (Senior Instructor: C. Stephen Foster). "Diagnosis, Medical and Surgical Therapy of Uveitis", Xth Congress European Society of Ophthalmology, Milan, Italy.
- 2/1996: Senior Instructor. VII Annual Course of Ophthalmology: Ocular Immunology and Uveitis. INDEM, Iberoamericana University, Santo Domingo, Dominican Republic.

- 10/1996: Senior Instructor. "Update on the Therapy of the immune-mediated problems of the ocular surface". 72 Congress of the Spanish Society of Ophthalmology. Madrid, 1996.
- 05/1997: Senior Instructor. V Ocular Immunology Course (Ocular Surface diseases), Sevilla, Spain. Foreign guests: Mr. Anthony Bron and Ken Kenyon, MD. University of Valladolid, Valladolid, Spain.
- 10/1997: Senior Instructor. "Uveitis: Medical and Surgical Treatment". 73 Congress Spanish Society of Ophthalmology. Granada.
- 10/1998: Senior Instructor. "Uveitis: Medical and Surgical Treatment". 74 Congress Spanish Society of Ophthalmology. Alicante.
- 5-7/03/99: Associate instructor: six lectures (3,5 hr total) (Senior instructor: C. Stephen Foster). "Uveitis". Danish Ophthalmological Society, Kolding, Denmark.
- 29-30/05/2000: Senior Instructor. VI Ocular Immunology Course (Dry Eye Syndrome: recent advances and therapeutic challenges), Valladolid, Spain. Foreign guests: Michael Stern, David Power (Allergan, Inc).
- 11/2000: Senior Instructor. "New therapeutic strategies for Dry Eye Syndrome". 76 Congress Spanish Society of Ophthalmology, Madrid.
- 26/09/2001: Senior Instructor. "Immunomodulation in Ophthalmology". 77 Congress Spanish Society of Ophthalmology, Barcelona.
- 30/09/2001: Senior Instructor. "New therapies for Dry Eye Syndrome". 77 Congress Spanish Society of Ophthalmology, Barcelona.
- 06/12/2003: "Ocular allergic disease". Course 4: Ocular Surface Diseases. XLVI Congress of the Portuguese Society of Ophthalmology. Vilamoura, Portugal.
- 29/09/2004: Senior Instructor: "Update on diagnostic techniques for ocular surface inflammatory diseases" (2 hr). 80 Congress Spanish Society of Ophthalmology, Córdoba, Spain.
- 09-12/02/2005: Senior Instructor V Ocular Immunology Course. Valladolid, Spain. Foreign guest: M. Stern, C. Stephen Pflugfelder.
- 21/09/2005: Senior Instructor "Limbal and amniotic membranes transplantation in our environment". National Network on Cooperative Research in Ophthalmology. CO-/13. (2 hr). 81st Congress Spanish Society of Ophthalmology, Zaragoza, Spain.
- 21/09/2006: Associate Instructor: "Tissue Transplantation on the ocular surface". National Network on Cooperative Research in Ophthalmology. CO-/13. (2 hr). 82nd Congress Spanish Society of Ophthalmology, La Coruña, Spain.

## EXPERIENCE IN CLINICAL TRIALS

- 1989: As co-investigator. Cyclosporin A for Dry Eye Syndrome. PI: C. Stephen Foster MD, Harvard Medical School, Boston, USA. Sponsored by Sandoz, USA.
- 09/2000-08/01: Safety and efficacy of Cyclosporin 0.05% unpreserved ophthalmic solution vs unpreserved artificial tears in patients with moderate to severe keratoconjunctivitis sicca. Clinical Trial 192371-503-01 (fase IIIb): Allergan, UK.
- 01/2003-10/2006: Fluocinolone Acetonide Implant in noninfectious uveitis patients (short title). Bausch & Lomb Inc, USA.

## CONSULTANTSHIPS

- 1996-1999: Alcon, Forth Worth, USA (clinical investigation)
- 1998-present: External reviewer (ANEP Committee) for research grant applications, Ministries of Health and Education of Spain.
- 1998-2001: Allergan Limited, UK. European Steering Group.
- 199-2000: Novartis, USA
- 1999-2003: Allergan Inc, Irvine, CA, USA.
- 2003-2008: Allergan Inc and Allergan Ltd

## JOURNAL REVIEWER

- Reviewer of several international journals.

- From 2003: member "Editorial Board" as "reviewing editor", Current Eye Research, United Kingdom.

## MEMBERSHIPS

- 1984: Sociedad Española de Oftalmología (SEO). *Spain*.
- 1988: Association for Research in Vision and Ophthalmology (ARVO). *USA*.
- 1988: Ocular Microbiology and Immunology Group (OMIG). *USA*.
- 1989: International Society of Eye Research (ISER).
- 1991: American Academy of Ophthalmology (AAO). *USA*.
- 1991: American Uveitis Society (AUS). *USA*.
- 1992: Massachusetts Eye and Ear Infirmary Alumni Association. *USA*.
- 1992: Member Especial de la Sociedad Colombiana de Oftalmología. *Colombia*.
- 1994: International Uveitis Study Group (IUSG).
- 1997: Sociedad Española de Alergología e Inmunología Clínica (SEAIC). *Spain*.
- 1998: International Ocular Inflammation Society (IOIS).
- 2000: Sjögren's Syndrome Foundation. *USA*.
- 2001: Tear Film & Ocular Surface Society (TFOS). *International*. (Medical and Scientific Advisory Board)
  - 2003-present: member of : "Medical and Scientific Advisory Board"
  - 2004-present: member of: "Nominating Committee"
- 2003: International Society of Dacriology and Dry Eye.
- 2006: Asociación Española Síndrome de Sjögren. *Spain*.
- 2006: International Society for Stem Cell Research (ISSCR).
- 2007: Spanish NanoMedicine Platform.
- 2008: International Ocular Surface Society.

## MAIN PUBLICATIONS (Indexed in PubMed)

1. Calonge M, Pastor JC, Herreras JM, González JL. Pharmacologic modulation of vascular permeability in ocular allergy in the rat. *Invest Ophthalmol Vis Sci* 1990;31:176-180. *USA*.
2. Foster CS, Calonge M. Atopic keratoconjunctivitis. *Ophthalmology* 1990;97:992-1000. *USA*.
3. Calonge M, Briggs RM, Levene RB, Saiga T, Bloch KJ, Allansmith MR. Early and late phases of ocular anaphylaxis in actively immunized guinea pigs. *Acta Ophthalmol (Copen)* 1990;68:470-476. *Denmark*.
4. Mehta MC, Calonge MC, Levene RB, Bloch KJ, Allansmith MR. Effect of topical dexamethasone on the ocular allergic reaction in passively sensitized guinea pigs. *Ophthalmic Res* 1990;22:351-358. *Swiss*
5. Calonge M, Ng B, Allansmith MR, Bloch KJ. Vascular permeability during the early and late phases of ocular anaphylaxis. *Invest Ophthalmol Vis Sci* 1992;33:55-59. *USA*.
6. Calonge M, Foster CS, Rice BA, Baer JC. Management of corneal complications in xeroderma pigmentosum. *Cornea* 1992;11:173-182. *USA*.
7. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing: a multicenter study. *Cornea* 1992;11:311-314. *USA*.
8. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. *Ophthalmology* 1992;99:1082-1088. *USA*.
9. Girbés T, Cítores L, Iglesias R, Ferreras JM, Muñoz R, Rojo MA, Arias FJ, García JR, Méndez E, Calonge M. Ebulin 1, a non-toxic novel type 2 ribosome-inactivating protein from *Sambucus ebulus* L. leaves. *J Biol Chem* 1993;268 (24):18195-18199. *USA*.



10. Girbés T, Cítores L, Ferreras JM, Rojo MA, Iglesias R, Muñoz R, Arias FJ, Calonge M, García JR, Mendez E. Isolation and partial characterization of nigrin-b, a non-toxic novel type 2 ribosome-inactivating protein from the bark of *Sambucus nigra* L. *Plant Mol Biol* 1993;22:1181-1186. *Holland*.
11. Lavid J, Ferreras JM, Calonge M, Saornil M, Aguirre C. Calcareous degeneration: report of two cases. *Cornea* 1995;14:97-102. *USA*.
12. Merayo-Llives J, Calonge M, Foster CS. Experimental model of allergic conjunctivitis to ragweed in guinea pig. *Curr Eye Res* 1995;14:487-494. *UK*.
13. Calvo P, Sánchez A, Martínez J, López MI, Calonge M, Pastor JC, Alonso MJ. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. *Pharm Res* 1996;13:311-315. *USA*.
14. Rodríguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D'Amico DJ, Foster CS. Referral patterns of uveitis in a tertiary eye care center. *Arch Ophthalmol* 1996;114:593-599. *USA*.
15. Juberías JR, Calonge M, Montero J, Ferreras JM, Saornil MA. Phlyctenular keratoconjunctivitis. A potentially blinding disorder. *Ocul Immunol Inflamm* 1996;4:119-123. *Holland*.
16. Calonge M, Montero JA, Ferreras JM, Juberías JR, Pastor JC. Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. *Ann Allergy Asthma Immunol* 1996;77:124-130. *USA*.
17. Ferreras JM, Pérez S, Pérez H, Calonge M, Pastor JC. Influence of topical anesthesia on tests diagnostic of blepharitis-associated dry eye syndrome. *Ocul Immunol Inflamm* 1997;5:33-41. *Holland*.
18. Diebold Y, Calonge M, Fernández N, Lázaro MC, Callejo S, Ferreras JM, Pastor JC. Characterization of epithelial primary cultures from human conjunctiva. *Graefe's Arch Clin Exp Ophthalmol* 1997;235:268-276. *Germany*.
19. Juberías JR, Calonge M, Gómez S, López MI, Calvo P, Ferreras JM, Alonso MJ. Efficacy of cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. *Curr Eye Res* 1998;17:39-46. *UK*.
20. Argüeso P, Ferreras JM, Calonge M, Cítores L, Pastor JC, Girbes T. Analysis of human ocular mucus: Effects of neuraminidase and chitinase enzymes. *Cornea* 1998;17:200-207. *USA*.
21. Diebold Y, Ferreras JM, Callejo S, Argüeso P, Calonge M. Carbomer-versus cellulose-based artificial-tear formulations: morphologic and toxicologic effects on a corneal cell line. *Cornea* 1998;17:433-440. *USA*.
22. Diebold Y, Calonge M, Carretero MV, Fernandez N, Ferreras JM. Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium. *J Oc Pharmacol Ther* 1998;14:517-531. *USA*.
23. Calonge M. Classification of ocular atopic/allergic disorders and conditions: an unsolved problem. *Acta Ophthalmol Scand* 1999; 77 (Suppl 228):10-13. *Denmark*.
24. Diebold Y, Calonge M, Callejo S, Lázaro MC, Bringas R, Ferreras JM. Ultrastructural evidence of mucus in human conjunctival epithelial cultures. *Curr Eye Res* 1999;19: 95-105. *UK*.
25. Calonge M. Ocular allergies: association with immune dermatitis. *Acta Ophthalmol Scand* 2000; 78 (Suppl 230):69-75. *Denmark*.
26. Sánchez-Tocino H, Saornil MA, Ferreras JM, Blanco G, Calonge M, Rodríguez de la Rúa E. Utilidad de la biopsia conjuntival como técnica diagnóstica (Conjunctival biopsy, a diagnostic technique. *Arch Soc Esp Oftalmol* 2001; 76:31-36. *Spain*.
27. Carrasco B, Calonge M, Rodríguez de la Rúa E, Aragón JA, Pastor JC. Neuroretinopatía macular aguda: a propósito de un caso (Acute neuroretinopathy: a case report). *Arch Soc Esp Oftalmol* 2001;76:319-322. *Spain*.
28. Calonge M. The treatment of dry eye. *Surv Ophthalmol* 2001;45:S227-S239. *USA*.
29. Calonge M. Atopic keratoconjunctivitis: a potentially blinding complication of atopic dermatitis. *Dev Allergy Asthma Immunol* 2001;1:49-55. *USA*.
30. Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Ferreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. *Ocul Immunol Inflamm* 2001;9:93-102. *Holland*.

31. Velilla S, Dios E, Herreras JM, Calonge M. Fuchs' heterochromic iridocyclitis: a review of 26 cases. *Ocul Immunol Inflamm* 2001;9:169-175. *Holland*.
32. Corrales RM, Diebold Y, Callejo S, Calonge M, Herreras JM, Sáez V, Mayo A. Lágrimas artificiales sin conservantes: estudio comparativo in vitro (In vitro toxicity in non-preserved artificial tears formulation). *Arch Soc Esp Oftalmol* 2001;76:613-620. *Spain*.
33. Calonge M. "Síndrome de Ojo Seco: ¿existen esperanzas para un tratamiento curativo?". Dry Eye Syndrome: is there any hope for a curative therapy?. Ed. letter. *Arch Soc Esp Oftalmol* 2002;77:119-120. *Spain*.
34. Dios E, Herreras JM, Calonge M, Velilla S. Sarcoidosis ocular. Estudio retrospectivo de 18 casos. Ocular sarcoidosis. Retrospective study of 18 cases. *Arch Soc Esp Oftalmol* 2002;77:301-308. *Spain*.
35. Vallelado AI, López MI, Calonge M, Sánchez A, Alonso MJ. Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats. *Curr Eye Res* 2002;24:39-45. *UK*.
36. Diebold Y, Corrales RM, Calonge M, Saez MV, Callejo S, Lazaro MC, Herreras JM. Human conjunctival epithelium in culture: a tool to assay new therapeutic strategies for dry eye. *Adv Exp Med Biol* 2002;506:307-311. *USA*.
37. Calonge M, Siemasko KF, Stern ME. Animal models of ocular allergy and their clinical correlations. *Curr Allergy Asthma Rep* 2003;3:345-351. *USA*.
38. Corrales RM, Galarreta DJ, Herreras JM, Calonge M, Chaves FJ. Expresión de los genes de mucinas MUC13, MUC15, MUC16 y MUC17 en el epitelio conjuntival normal humano in vivo. Normal human conjunctival epithelium expresses MUC13, MUC15, MUC16 and MUC17 mucin genes *Arch Soc Esp Oftalmol* 2003;78:375-382. *Spain*.
39. Diebold Y, Calonge M, Enríquez de Salamanca A, Callejo S, Corrales RM, Sáez V, Siemasko KF, Stern ME. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. *Invest Ophthalmol Vis Sci* 2003;44:4263-4274. *USA*.
40. Corrales RM, Calonge M, Herreras JM, Saez V, Chaves FJ. Human epithelium from conjunctival impression cytology expresses MUC7 mucin gene. *Cornea* 2003;22:665-671. *USA*.
41. Corrales RM, Calonge M, Herreras JM, Saez V, Mayo A, Chaves FJ. Levels of mucin gene expression in normal human conjunctival epithelium in vivo. *Curr Eye Res* 2003;27:323-328. *UK*.
42. Gabela MI, González MJ, Mayo A, Calonge M, Síntomas y signos de Ojo Seco en usuarios de lentes de contacto hidrofílicas: relación con el hábito de fumar. (Dry eye signs and symptoms in hydrogel contact lens wearers related with smoking habit). *Arch Soc Esp Oftalmol* 2003;78:543-548. *Spain*.
43. Sanabria RM, Rodríguez de la Rúa E, Arangón JA, Calonge M, Saornil MA, Pastor. JC. Can the use of silicone oil increase the risk of sympathetic ophthalmia?. *Arch Soc Esp Oftalmol* 2003;78:39-42. *Spain*.
44. Calonge M, Diebold Y, Sáez V, Enríquez de Salamanca A, García-Vázquez C, Corrales RM, Herreras JM. Impression cytology of the Ocular Surface: a review. *Exp Eye Res* 2004; 78: 457-472. *UK*.
45. Torres RM, Calonge M. Macular edema as the only ocular finding of tuberculosis. *Am J Ophthalmol* 2004;138:1048-1049. *USA*.
46. Feitosa de Souza C, Calonge M, Pastor JC, Bailez C, Saornil MA, Méndez MC. "Oftalmía simpática postvitrectomía tras traumatismo y tamponamiento con perfluorocarbono líquido". Sympathetic ophthalmia post-vitrectomy following trauma and perfluorocarbon liquid tamponade. *Arch Soc Esp Oftalmol* 2004;79:553-556. *Spain*.
47. Torres RM, Yáñez B, Herreras JM, Calonge M. Enfermedad de Behçet ocular. Estudio retrospectivo. Ocular Behçet disease. Retrospective study. *Arch Soc Esp Oftalmol* 2004;79:599-604. *Spain*.
48. Calonge M. Dry eye disease: current therapies and related systemic diseases. *Asian J Ophthalmol* 2005;7(2):12-15.
49. Enríquez de Salamanca A, Siemasko KF, Diebold Y, Calonge M, Gao J, Juarez-Campo M, Stern ME. Expression of muscarinic and adrenergic receptors in the normal human conjunctival epithelium. *Invest Ophthalmol Vis Sci* 2005;46:504-513. *USA*.

50. Calonge M, Enríquez de Salamanca A. The role of the conjunctival epithelium in ocular allergy. *Curr Opin Allergy Clin Immunol* 2005;5:441-445. *USA*. (solicited).
51. Calonge M, Enríquez de Salamanca A, Siemasko KF, Diebold Y, Gao J, Juárez-Campo M, Stern ME. Variation in the expression of inflammatory markers and neuro-receptors in human conjunctival epithelial cells. *Ocul Surf* 2005;3:S145-S148. *USA*. (solicited).
52. Stern ME, Siemasko KF, Gao J, Calonge M, Niederhorn JY, Pflugfelder SC. Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. *Ocul Surf* 2005;3:S161-S164. *USA*. (solicited).
53. McDermott AM, Perez V, Huang AJW, Pflugfelder SC, Stern ME, Baudouin C, Beuerman RW, Burns AR, Calder VL, Calonge M, Chodosh J, Coster D, Dana R, Hazlett LD, Jones DB, Kim SK, Knop E, Li DQ, Mitchell BM, Niederhorn JY, Pearlman E, Wilhelmus KR, Kurie E. Pathways of corneal and ocular surface inflammation: A perspective from the Cullen Symposium. *Ocul Surf* 2005;3:S131-S138. *USA*. (solicited).
54. Martínez-Osorio H, Calonge M, Torres J, González F. Cat-scratch disease (ocular bartonellosis) presenting as bilateral recurrent iridocyclitis. *Clin Infect Dis* 2005;40:43-45. *USA*.
55. Diebold Y, Enríquez de Salamanca A, Calonge M, Callejo S, Saez V, Stern ME. Alpha adrenergic receptors are present in normal human conjunctiva. *Curr Eye Res* 2005;30:1121-1129. *UK*.
56. Enríquez de Salamanca A, Diebold Y, Calonge M, García-Vazquez C, Callejo S, Vila A, Alonso MJ. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and *in vivo* tolerance. *Invest Ophthalmol Vis Sci* 2006;47:1416-1425. *USA*.
57. Motterle L, Diebold Y, Enríquez de Salamanca A, Saez V, Garcia-Vazquez C, Stern ME, Calonge M, Leonardi A. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. *Arch Ophthalmol* 2006;124:462-468. *USA*.
58. Martínez-Osorio H, Fuentes-Paez G, Calonge M. Severe keratopathy in paediatric Cogan's syndrome. *Rheumatology* 2006;45:1576-1577.. *USA*.
59. Enríquez de Salamanca A, Calonge M. Muscarinic receptors in the ocular surface. *Curr Opin Allergy Clin Immunol* 2006;6:379-382. *USA*. (solicited).
60. Fuentes-Paez G, Martínez-Osorio H, Herreras JM, Calonge M. Subretinal fibrosis and uveitis syndrome associated with ulcerative colitis. *Int J Colorectal Dis* 2007;22:333-334.
61. Diebold Y, Jarrín M, Sáez V, Carvalho ELS, Orea M, Calonge M, Seijo B, Alonso MJ. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). *Biomaterials* 2007;28:1553-1564. *UK*.
62. Bonini S, Rasi G, Brusasco V, Carlsen KH, Crimi C, Popov T, Schultze-Werninghaus G, Gramiccioni C, Bonini M, Passali D, Bachert C, van Cauwenberge PB, Bresciani M, Bonini S, Calonge M, Montan PG, Srapiao Dos Santos M, Belfort Jr R, Lambiase A, Sacchetti M. Nonspecific provocation of target organs in allergic diseases: EAACI-GA2LEN consensus report. *Allergy* 2007;62:683-694 *USA*.
63. Bron AJ, Bron AJ, Abelson MB, Ousler G, Pearce E, Tomlinson A, Yokoi N, Smith JA, Begley C, Caffery B, Nichols K, Schaumberg D, Schein O, Calonge M, Baudouin C, Goto E, Grus F, Paugh J. Methodologies to diagnose and monitor Dry Eye disease: report of the diagnostic methodology subcommittee of the Internacional Dry Eye WorkShop (2007). *Ocul Surf* 2007;5:108-152. *USA*.
64. Fuentes-Páez G, Méndez MC, Montañés J, Herreras JM, Saornil MA, Calonge M. Conjunctival pigmentation in Stevens-Johnson syndrome. *Ann Ophthalmol* 2007;39:152-157. *USA*.
65. Fuentes-Páez G, Méndez MC, Montañés J, Herreras JM, Saornil MA, Calonge M. Conjunctival pigmentation in Stevens-Johnson syndrome. *Compr Ther* 2007;33:99-103. *Ann Ophthalmol* 2007;39:152-157. *USA*.

66. González-García MJ, González-Sáiz A, De la Fuente B, Morilla-Grasa A, Mayo-Isicar A, San José J, Feijó J, Stern ME, Calonge M: Exposure to a controlled adverse environment impairs the ocular surface of subjects with minimally symptomatic dry eye. *Invest Ophthalmol Vis Sci* 2007;48:4026-4032. USA.
67. Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. *Curr Opin Allergy Clin Immunol* 2007;7:442-445. USA.
68. Calonge M, Agahan A, Herreras JM. Afectación ocular en la enfermedad injerto contra huésped. *Method Find Exp Clin Pharmacol* 2007;29(Suppl.1):69-72. Spain.
69. Torres J, Fernández I, Quadrado MJ, Herreras JM, Rodríguez-Ares MT, Benítez del Castillo JM, Alio J, Muñoz MF, Calonge M. Estudio retrospectivo sobre trasplantes de limbo. Limbal transplantation: multicenter retrospective case series analysis. *Arch Soc Esp Oftalmol* 2008;83:417-422. Spain.
70. Enríquez de Salamanca A, Calonge M. Cytokines and chemokines in immune-based ocular surface inflammation. *Experts Rev Clin Immunol* 2008;4:457-467.
71. Siemasko KF, Gao J, Calder VL, Hanna R, Calonge M, Pflugfelder SC, Niederkorn JY, Stern ME. In vitro expanded CD4+CD25+Foxp3+ regulatory T cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation. *Invest Ophthalmol Vis Sci* 2008;49. USA.
72. Enríquez de Salamanca A, Calder V, Gao J, Galatowicz G, García-Vázquez C, Fernandez I, Stern ME, Diebold Y, Calonge M. Cytokine responses by conjunctival epithelial cells: An in vitro model of ocular inflammation. *Cytokine*. 2008;44:160-167.
73. Agahan ALD, Pastor JC, Méndez C, Saornil MA, Herreras JM, Calonge M. Masquerade syndrome: A case of primary uveal extranodal marginal zone lymphoma. *Asian J Ophthalmology*. Accepted.
74. Martínez-Osorio H, Juárez-Campo M, Diebold Y, Girotti A, Alonso M, Arias J, Rodríguez-Cabello JC, García-Vázquez C, Calonge M. Genetically engineered elastin-like polymer as a matrix to culture cells from the ocular surface. *Current Eye Research* 2008. Accepted

#### Book chapters

1. Calonge M. Esclerouveítis. Capítulo IV: Uveítis no infecciosas o inespecíficas. En: Uveítis: Sinopsis Diagnóstica y Terapéutica. Belfort R, Couto CA, Martínez Castro F, eds. Ciba Vision Ophthalmics. Latinoamérica, 1997:109-115. *Brasil*.
2. Foster CS, Calonge M. Management of severe atopic kerato-conjunctivitis. In: Usui M, Ohno S, Aoki K, eds. *Ocular Immunology Today*. The Netherlands: Elsevier Science Publishers B.V (Biomedical Division); 1990:33-36.
3. Calonge M. Medication-induced uveitis. In: *Diagnosis and treatment of uveitis*. Foster CS, Vitale A, eds. W.B. Saunders, Philadelphia, 2002: 859-868.
4. Calonge M, Stern ME. Conjunctiva and tear film maintenance. En: *Dry Eye and the Ocular Surface Disorders*. Pflugfelder CS, Stern ME, Beuerman RW, eds. Marcel Dekker Inc., New York, 2004. ISBN: 0-8247-4702-X. USA.
5. Calonge M. (associate editor) Diagnostic Tests. En: *Blepharitis and Conjunctivitis. Guideline for Diagnosis and Treatment*. Benezra D, ed. Barcelona: Glosa, 2006:56-71. ISBN: 84-7429-268-9.
6. Calonge M. (associate editor) Blepharitis. En: *Blepharitis and Conjunctivitis. Guideline for Diagnosis and Treatment*. Benezra D, ed. Barcelona: Glosa, 2006:56-71. ISBN: 84-7429-268-9.
7. Martínez-Osorio H, Herreras JM, Calonge M. Síndrome de Sjögren. En: *Enfermedades Inflamatorias Oculares*. Contacto de primera vez, ed. Informed S.A. Mexico, DF. 2007:68-73.
8. Martínez-Osorio H, Blanco G, Calonge M. Escleritis. En: *Enfermedades inflamatorias oculares*. Contacto de primera vez, ed. Informed S.A. Mexico, DF. 2007:172-178.

Proceedings and Abstracts (Internationals only, since 2003).

1. Calonge M, Corrales RM, Herreras JM, Saez V, Diebold Y, Chaves FJ. Changes in human conjunctival mucin gene expression from the in vivo to the in vitro situation. First SERI-ARVO Meeting on Research in Vision and Ophthalmology 2003;p131:161. *Singapore.*
2. Diebold Y, Enríquez de Salamanca A, Siemasko K, Callejo S, Calonge M, Stern ME. Immunodetection of muscarinic and adrenergic receptors in epithelial cells from human conjunctiva. First SERI-ARVO Meeting on Research in Vision and Ophthalmology 2003;p103:45. *Singapore.*
3. Stern ME, Pflugfelder SC, Beuerman RW, Calonge M. The role of immune-based inflammation in the pathogenesis of dry eye. Symposium 8: Ocular Inflammation. First SERI-ARVO Meeting on Research in Vision and Ophthalmology 2003;p91. *Singapore.*
4. Gao J, Siemasko, Diebold Y, Enriquez de Salamanca A, Vu C, Calonge M, Stern ME. In vitro models of ocular inflammation using normal human conjunctival cells. IOVS 2003;44:ARVO E-Abstract 683. USA.
5. Calonge M, Corrales RM, Sáez V, Mayo A, Herreras JM, Stern ME, Chaves FJ. Alteration of conjunctival mucin gene expression in tear deficient dry eye syndrome. IOVS 2003;44:ARVO E-Abstract 2508. USA.
6. Stern ME, Siemasko K.F, Gao J, Niederkorn JY, Calonge M, Pflugfelder SC. Effects of IFN $\gamma$  and Cyclosporin A (CsA) on tear production in a mouse model of keratoconjunctivitis sicca (KCS). IOVS 2003;44:ARVO E-Abstract 2531. USA.
7. Galarreta DJ, Corrales RM, Herreras JM, Gonzalez MJ, Arranz I, Sáez V, Mayo A, Cisneros AB, Calonge M, Chaves FJ. Levels of antioxidant enzyme genes in conjunctival impression cytology specimens from hydrogel contact lenses wearers. IOVS 2003;44:ARVO E-Abstract 3682. USA
8. Gonzalez MJ, Arranz I, Galarreta DJ, Cisneros AB, Calonge M, Herreras JM. Comparison of central corneal thickness measured with ultrasonic pachometer, Orbscan and OCT. IOVS 2003;44:ARVO E-Abstract 3692. USA
9. Arranz I, Gonzalez MJ, Galarreta DJ, Cisneros AB, Calonge M, Herreras JM. Low water content hydrogel contact lenses (HCL) induce corneal irregularity. IOVS 2003;44:ARVO E-Abstract 3701. USA
10. Motterle L, Saez V, Garcia C, Diebold Y, Enriquez de Salamanca A, Herreras JM, Stern ME, Leonardi A, Calonge M. Expression of neurotransmitter receptors and vip in conjunctival biopsies of venal keratoconjunctivitis patients. IOVS 2003;44:ARVO E-Abstract 3743. USA.
11. Herreras JM, Corrales RM, Galarreta DJ, Arranz I, Gonzalez MJ, Garcia C, Calonge M, Sáez V, Mayo A, Chaves FJ. Antioxidant enzyme genes expression in conjunctival epithelium of normal subjects. IOVS 2003;44:ARVO E-Abstract 3776. USA.
12. Corrales RM, Galarreta DJ, Herreras JM, Gonzalez MJ, Arranz I, Sáez V, Mayo A, García-Vázquez C, Calonge M, Chaves FJ. Prospective variation in the expression of the conjunctival mucin genes Muc5ac, Muc7, Muc 16, and Muc17 before, during and after contact lens wear. IOVS 2003;44:ARVO E-Abstract 3777. USA.
13. Enriquez de Salamanca A, Diebold Y, Calonge M, Siemasko K. Gao J, Stern ME. Western blot analysis of muscarinic and adrenergic receptors in a normal human conjunctival (NHC) epithelial cell line. IOVS 2003;44:ARVO E-Abstract 3783. USA
14. Siemasko KF, Enriquez de Salamanca A, Gao J, Diebold Y, Calonge M, Stern ME. Effect of IFN $\gamma$  on muscarinic and adrenergic receptor expression in a normal human conjunctival (NHC) epithelial cell line: flow cytometry study. IOVS 2003;44:ARVO E-Abstract 3803. USA.
15. Galarreta DJ, Corrales RM, Herreras JM, Arranz I, González MJ, Sáez V, García C, Mayo A, Calonge M, Chaves FJ. Comparison of antioxidant enzymes genes expression changes in conjunctival epithelium induced by non ionic hydrogel contact lenses with different oxygen permeability. IOVS 2004;45: ARVO E-abstract 1475. USA.
16. Herreras JM, Galarreta DJ, Corrales RM, González MJ, Arranz I, Sáez V, García C, Mayo A, Calonge M, Chaves FJ. Comparison of mucin genes expression alterations in conjunctival epithelium induced by high and low water content hydrogel contact lenses. IOVS 2004;45: ARVO E-abstract 1476. USA.
17. Enriquez de Salamanca A, Diebold Y, Calonge M, Callejo S, Siemasko KF, Gao J, Stern ME. Presence of Alpha 2-adrenergic receptor subtypes in the normal human conjunctiva. IOVS 2004;45: ARVO E-abstract 1480. USA.
18. Stern ME, Siemasko KF, Gao J, Duong A, Calder VL, Pflugfelder SC, Calonge M, Niederkorn JY. The role of IFN- $\gamma$  in the pathophysiology of Th2 inflammation in the mouse model of allergic conjunctivitis. IOVS 2004;45: ARVO E-abstract 1503. USA.
19. González MJ, Galarreta DJ, Arranz I, Mayo A, Calonge M, Herreras JM. Corneal thickness changes after one year of hydrogel contact lens use. IOVS 2004;45: ARVO E-abstract 1571. USA.
20. Torres RM, Calonge M. Macular Edema as the only ocular finding of tuberculosis. Sixth International Symposium on Uveitis. Venezia-Mestre, Italy, September 10-22, 2004.
21. Torres RM, Herreras JM, Yáñez B, Calonge M. Ocular Behçet Disease. Retrospective Study. Sixth International Symposium on Uveitis. Venezia-Mestre (Italy), September 10-22, 2004.
22. Calonge M, Diebold Y, Enriquez de Salamanca A, Gao J, Siemasko KF, Juarez-Campo M, Stern ME. Conjunctival epithelium biology: role of conjunctival epithelial cells in vitro. *The Ocular Surface* 2005;3:S51. USA.
23. Calonge M, Enriquez de Salamanca A, Siemasko KF, Diebold Y, Motterle L, Leonardi A, Gao J, Stern ME. Expression of neurotransmitter receptors in normal and inflamed human conjunctival epithelium. *The Ocular Surface* 2005;3:S52. USA.
24. Stern ME, Siemaski KF, Gao J, Calonge M, Calder VL, Pflugfelder SC, Niederkorn JY. Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. *The Ocular Surface* 2005;3:S116. USA.
25. Siemasko KF, Gao J, Calonge M, Calder VL, Pflugfelder SC, Niederkorn JY, Stern ME. IFN- $\gamma$ , A Th 1-type cytokine, is functionally important in Th 2 ocular surface inflammation in the mouse model of allergic conjunctivitis. *The Ocular Surface* 2005;3:S112. USA.
26. Gao J, Siemasko KF, Vu C, Nguyen L, Calonge M, Stern ME. The role of NF- $\kappa$ B in human conjunctival epithelial cell inflammation. *The Ocular Surface* 2005;3:S64. USA.
27. Diebold Y, Enriquez de Salamanca A, Jarrin M, Calonge M, Vila A, Carvalho ELS, de la Fuente M, Seijo B, Alonso MJ. Nanotechnologies for ocular surface disorder management: a promising approach. *The Ocular Surface* 2005;3:S56. USA.

28. Calonge M, Enríquez de Salamanca A, Siemasko K, Diebold Y, Motterle L, Leonardi A, Gao J, Stern ME. Altered expression of neurotransmitter receptors in conjunctival epithelium under inflammatory conditions. 2nd SERI-ARVO Meeting on Research in Vision and Ophthalmology, Singapore. Am J Ophthalmol 2005;139:S43.
29. Stern ME, Siemasko KF, Gao J, Calonge M, Pflugfelder SC, Niederkorn JY. The role of IFN- $\epsilon$  in a mouse model of allergic conjunctivitis. 2nd SERI-ARVO Meeting on Research in Vision and Ophthalmology, Singapore. Am J Ophthalmol 2005;139:S5.
30. Gonzalez MJ, Gonzalez-Saiz A, Herreras JM, Mayo A, de la Fuente B, San Jose J, Feijo J, Stern M, Calonge M. Hydrogel contact lens (HCL) wear in controlled adverse environment (CAE) condition. IOVS 2005;46:ARVO E-abstract 2066. USA.
31. Diebold Y, Enríquez de Salamanca A, Calonge M, Vila A, Carvalho ELS, de la Fuente M, Seijo B, Alonso MJ. Ocular surface in vivo tolerance to new nanoparticulate polymer systems designed for drug delivery. IOVS 2005;46:ARVO E-abstract 2048. USA.
32. Siemasko KF, Gao J, Enríquez de Salamanca A, Diebold Y, Calder VL, Calonge M, Stern ME. Inflammatory cytokine effects on co-stimulatory molecule and chemokine expression in the human conjunctival epithelial cell line, IOBA-NHC. IOVS 2005;46:ARVO E-abstract 2687. USA.
33. Calonge M, Corrales RM, Sáez V, García-Vázquez C, Mayo A, Chaves FJ, Stern ME, Herreras JM. Can Ocular mucin gene levels be used as an investigational diagnostic test for Dry Eye?. IOVS 2005;46:ARVO E-abstract 4465. USA.
34. Torres J, Herreras JM, Quadrado MJ, Fonseca P, Rodríguez-Ares MT, Benítez del Castillo JM, Alio J, Muñoz-Moreno MF, Calonge M. Limbal transplantation in ocular surface disease: multicenter retrospective case series analysis. IOVS 2005;46:ARVO E-abstract 4974. USA.
35. Juárez-Campo M, Diebold Y, García-Vázquez C, Girotti A, Alonso M, Arias FJ, Rodríguez-Cabello JC, Calonge M. Development of a biopolymer-epithelium complex for ocular surface reconstruction. IOVS 2005;46:ARVO E-abstract 4990. USA.
36. Ribeiro A, Girotti A, Arias FJ, Alonso M, Rodríguez-Cabello JC, Juárez-Campo M, Diebold Y, Calonge M. Design and bioproduction of recombinant elastin-like polymers as advanced matrices for tissue engineering. 6th International Symposium on Frontiers in Biomedical Polymers 16-19/06, 2005. Granada, Spain.
37. Arias FJ, Girotti A, Calonge M, Diebold Y, Juárez-Campo M, Reboto V, Rodríguez-Cabello JC. Multi-bioactive recombinant elastin-like polymer: mimicking the complexity of the extracellular matrix. European Polymer Congress. 27/06-01/07, 2005. Moscow, Russia.
38. Girotti A, Rodríguez-Cabello J.C, Arias F. J, Alonso M, Testera A.M, Juárez-Campo M, Diebold Y, Calonge M. Design and production of recombinant elastin-like polymers as advanced matrixes for tissue engineering. European Conference on Biomaterials. 11-15/09, 2005. Sorrento, Italia. Internacional.
39. Stern ME, Pflugfelder SC, Siemasko KF, Gao J, de Paiva CS, Corrales RM, Niederkorn JY. Desiccating stress to the ocular surface induces a transferable T-Cell mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. 9th International Symposium on Sjögren Syndrome. 27-29 Abril, 2006. Washington DC, USA.
40. Fuentes-Paez G, Gonzalez-Garcia MJ, Gonzalez-Saiz A, Morilla-Grasa A, Enríquez de Salamanca A, Garcia-Vazquez C, Herreras JM, Calonge M. Evaluation of clinical tolerance to soft contact lens (SCL) care systems. IOVS 2006;47:ARVO E-abstract 107. USA.
41. Gonzalez-Garcia MJ, Gonzalez-Saiz A, Herreras JM, de la Fuente B, San Jose J, Feijo J, Mayo a, Stern ME, Calonge M. Environmental chamber as a diagnostic tool for marginal dry eye sufferers. IOVS 2006;47:ARVO E-abstract 241. USA.
42. Herreras JM; Fuentes-Paez G, Cordero Y, Almaraz A, Calonge M. Prevalence of dry eye syndrome in Valladolid (Spain). IOVS 2006;47:ARVO E-abstract 260. USA
43. Gao J, Siemasko KF, Vu C, Niederkorn JY, Pflugfelder SC, Calonge M, Calder VL, Stern ME. The effect of corneas from dry eye mice on peripheral lymphocyte proliferation. IOVS 2006;47:ARVO E-abstract 4363. USA
44. Martinez-Osorio H, Garcia-Vazquez C, Saez V, Fernandez I, Calonge M, Diebold Y. Effect of calcium concentration on the proliferation of IOBA-NHC cells grown on two different substrates. IOVS 2006;47:ARVO E-abstract 4933. USA.
45. Enríquez de Salamanca A, Gao J, Calder V, Galatowicz G, Siemasko KF, Garcia-Vazquez C, Stern ME, Calonge M. Cytokine/Chemokine secretion by human conjunctival epithelial cells stimulated with Th1 or Th2 derived cytokines. IOVS 2006;47:ARVO E-abstract 4937. USA
46. Calonge M, Enríquez de Salamanca A, Garcia-Vazquez C, Stern M. Specific patterns of conjunctival epithelial barrier alteration induced by Th1 versus Th2 cytokines. IOVS 2006;47:ARVO E-abstract 4938. USA.
47. Diebold Y, Enríquez de Salamanca A, Orea M, Saez V, Garcia-Vazquez C, de la Fuente M, Sejo B, Alonso MJ, Calonge M. In vivo uptake of nanoparticulate drug delivery systems by ocular surface structures. IOVS 2006;47:ARVO E-abstract 5584. USA.
48. Diebold Y, García-Vázquez C, Sáez V, Calonge M, Orea M, Méndez MC, de la Fuente M, Seijo B, Alonso MJ. In vivo study of new chitosan-hyaluronic acid nanoparticles. 33rd Meeting and Exposition of the Controlled Release Society. 22-26/07/2006. Viena, Austria.
49. Calonge M, Enríquez de Salamanca A, Calder V, García-Vázquez C, Gao J, Siemasko KF, Galatowicz G, Diebold Y, Stern ME. Role of Conjunctival Cells in Inflammation. ICER 2006, 12.
50. Stern ME, Gao J, Siemasko KF, Vu C, Niederkorn JY, Pflugfelder SC, Calonge M, Calder VL. Immunogenic role of the cornea from the dry eye mice in peripheral T cell proliferation. ICER 2006,80.
51. Diebold Y, Martinez-Osorio H, Fernandez I, Saez V, Calonge M. Recovery of viable cells from human conjunctival epithelium by minimally invasive techniques. IOVS 2007;48:ARVO
52. Enríquez de Salamanca A, Carreño E, García-Vázquez C, Galatowicz G, Calder V, Stern ME, Calonge M. In Vitro TGF- $\beta$  receptor expression and TGF- $\beta$  secretion by conjunctival epithelial cells under basal and inflammatory conditions. IOVS 2007;48:ARVO

53. Martinez-Osorio H, Calonge M, Fernandez I, Corell A, Saez V, Diebold Y. Culture of human conjunctival cells recovered by brush cytology. IOVS 2007;48:ARVO.
54. Stern ME, Siemasko KF, Gao J, Calder VL, Hanna R, Calonge M, Pflugfelder SC, Niederkorn JY. In Vitro expanded CD4+CD25+FoxP3+ Regulatory T Cells inhibit Ocular Surface inflammation in a mouse model of dry eye. IOVS 2007;48:ARVO.
55. Siemasko KF, Gao J, Calder VL, Calonge M, Pflugfelder SC, Niederkorn JY, Stern ME. Expanded mouse DC4+CD25+FoxP3+ Regulatory T cells maintain a normal phenotype in vitro. IOVS 2007;48:ARVO.
56. Gao J, Siemasko KF, vu C, Chen R, Pflugfelder SC, Niederkorn JY, Calder VL, Calonge M, Stern ME. Immunogenic role of dry eye corneas in lymphocyte proliferation and effect of TGF- $\beta$ 1 and T regulatory cells in dry eye cornea-induced lymphoproliferation- IOVS 2007;48:ARVO.
57. Stern ME, Pflugfelder SC, Siemasko KF, Gao J, Calder VL, Calonge M, Niederkorn JY. The ocular surface plays an antigenic role in the initiation of a mouse model of dry eye disease. IOVS 2008;49:ARVO (abstract E-188)
58. Gao J, Siemasko KF, Niederkorn JY, Calder VL, Calonge M, Pflugfelder SC, Wheeler LA, Stern ME. Corneas exposed to desiccating stress are immunogenic and induce T cell proliferation in mice with experimental lacrimal keratoconjunctivitis (LKC). IOVS 2008;49:ARVO (abstract E-192).
59. Siemasko K, Gao J, Calonge M, Calder VL, Pflugfelder SC, Niederkorn JY, Stern ME. Luminex analysis of tears from CD4+ T cell adoptively transferred mouse model of Sjögren's syndrome-like lacrimal keratoconjunctivitis. IOVS 2008;49:ARVO (abstract E-197).
60. Castellanos E, Torres J, Fernandez I, Martinez-Osorio H, Herreras JM, Stern ME, Calonge M. Preponderance of evaporative over aqueous deficient-type dry eye syndrome in patients with chronic dry-eye related symptoms. IOVS 2008;49:ARVO (abstract E-2371).
61. Whitcup SM, Gao J, Wheeler LA, Calonge M, Stern ME. Cytokine and chemokine profile in experimental autoimmune uveitis. IOVS 2008;49:ARVO (abstract E-2866)
62. Enriquez-de-Salamanca A, Garcia-Vazquez C, Calder V, Stern ME, Calonge M. In vitro TGF-beta effect on cytokine/chemokine and metalloproteinases (MMPs) secretion by human ocular surface epithelial cells. IOVS 2008;49:ARVO (abstract E-6041).
63. Teson-Yudego M, Gonzalez-Garcia MJ, Morejon A, S. Sancho Velasco D, Fernandez I, Calonge M. Influence of visual acuity, refractive error and ocular dominance on corneal sensitivity. IOVS 2008;49:ARVO (abstract E-1046).
64. Gonzalez-Garcia MJ, Teson M, Morejon A, Sancho S, Velasco D, Fernandez I, Acosta MC, Calonge M. Reproducibility and safety of corneal sensitivity evaluation with Belmonte's esthesiometer. IOVS 2008;49:ARVO (abstract E-2561).
65. Contreras L, López-García A, Calonge M, de la Fuente M, Seijo B, Alonso MJ, Diebold Y. Hyaluronan receptor-mediated uptake of hyaluronic acid-chitosan nanoparticles in ocular epithelial cells. IOVS 2008;49:ARVO (abstract E-4785).
66. Diebold Y, Contreras-Ruiz L, López-García A, Calonge M, de la Fuente M, Seijo B, Alonso MJ. Intracellular trafficking of hyaluronic acid-chitosan nanoparticles in ocular epithelial cells. IOVS 2008;49:ARVO (abstract E-4789).
67. Torres J, Enriquez-de-Salamanca A, Fernandez I, Rodriguez-Ares MT, Quadrado MJ, Murta J, Benitez-del-Castillo JM, Calonge M. Activation of MAPK signaling pathway and NF- $\kappa$ B activation in pterygium and ipsilateral pterygium-free conjunctival specimens. IOVS 2008;49:ARVO (abstract E-6037).
68. Corell A, Martínez-Osorio H, Calonge M, Gutierrez-San José E, Lopez-García A, Fernandez I, Diebold Y. Flow cytometry characterization of conjunctival cells obtained by brush cytology. IOVS 2008; 49: ARVO (abstract E-6048).
69. Contreras-Ruiz L, López-García A, Calonge M, de la Fuente M, Seijo B, Alonso MJ, Diebold Y. A hyaluronic acid receptor-mediated active transport mechanism is involved in the uptake of hyaluronic acid-chitosan nanoparticles in ocular epithelial cells. (abstract). 2<sup>nd</sup> Cellular Delivery of Therapeutic Macromolecules International Symposium. June, 2008. Cardiff, UK.
70. Corrales RM, De la Mata A, Lopez M, Saez MV, De la Paz M, Herreras JM, Calonge M. New markers for quantifying limbal stem cells (LSC). (abstract). Stem Cells Europe Conference and Exhibition. September, 2008. Amsterdam.
71. Corrales RM, De la Mata A, López M, Saez MV, De la Paz M, Nieto T, Herreras JM, Calonge M. New limbal stem cells markers (abstract). The TERMIS-NA 2008 Conference and Exposition. December, 2008. San Diego, CA, USA.